as the number of symptomatic arterial disease locations increases. A cost-utility analysis was undertaken comparing two years of clopidogrel treatment with aspirin treatment for patients with a previous history of MI, who then sustain an IS or a peripheral arterial disease (PAD) event. These patients are referred to as 'high-risk'. METHODS: A model was constructed to simulate hypothetical 'high-risk' patients. The time horizon was that of patient lifetime with only direct medical costs considered. Health states included were vascular death, non-fatal IS events and non-fatal MI events. The risk of future events in the 'high-risk' group compared with patients who had sustained a single event (MI, IS or PAD) was calculated from the CAPRIE trial and showed an 81% increase. This ratio was applied to previously published risks of vascular death, non-fatal IS and non-fatal MI for UK patients with a single event to calculate the event rates for 'high-risk' patients. The relative risks (and 95% confidence intervals) of clopidogrel compared with aspirin in 'high-risk' patients in the CAPRIE trial were 0.87 (0.63-1.19), 0.83 (0.60-1.15) and 0.53 (0.32-0.86) for vascular death, nonfatal IS and non-fatal MI events respectively. Costs and utilities associated with events were taken from literature reviews and were discounted at 3.5% per annum. Probabilistic sensitivity analyses were undertaken. RESULTS: The mean cost per QALY for clopidogrel compared with aspirin was Յ5443 (95% confidence interval Յ2332 to dominated). The probability of the cost per QALY being below Յ20,000, a significant threshold for cost-effectiveness in the UK, was 79%. CONCLUSION: The model suggests that, in patients with a previous MI event and a subsequent IS or PAD event, clopidogrel can be considered cost-effective compared with aspirin in terms of current UK thresholds.
Patel VA, McGhan WF University of the Sciences in Philadelphia, Philadelphia, PA, USA OBJECTIVE: Proper diagnosis of Deep Vein Thrombosis (DVT) at the earliest time is very important so that appropriate therapy can be initiated. Various diagnostic tests have been developed for DVT, but most of them have poor sensitivity and specificity. Due to the above issues, it is very important that diagnosis strategies be developed which are cost-effective. METHODS: Costeffectiveness was analyzed using a decision model from TreeAge Pro Suite 2007 software. Outcomes considered were costs, adverse events and quality adjusted life years (QALYs). Probabilities were calculated using Bayes' revision method that utilized sensitivity and specificity of the diagnostic tests along with the pretest probability of developing the disease. Quality of life and costs data were pooled from literature reviews. QALYs were calculated using life expectancy tables. Costs in pounds were converted to US dollars and adjusted through use of Consumer Price Index data from Bureau of Labor Statistics. RESULTS: With a cost-effectiveness ratio of $32.4995 per QALY, the following strategy dominated other alternate strategies-Perform venography if D-dimer test is positive. Otherwise, if D-dimer test is negative then no treatment is given. If venography shows abnormal results, treatment is given otherwise for normal results, no treatment is given. Sensitivity analysis showed that this strategy remained cost-effective even when all costs were varied by 25%. The model results were affected by the sensitivity of the diagnostic tests. CONCLUSION: Based on this analysis, it would be cost-effective if symptomatic patients are diagnosed with the strategy after classifying them according to Wells score. Further research needs to be done to see if cost of venography is offset by decrease in hospitalization of those who later develop severe form of DVT. Health care providers should consider patient population distribution among the risk groups defined by Wells score before generalizing the finding. To assess long-term reduction of cardiovascular (CV) events and cost-effectiveness of the use of rosuvastatin (RSV), atorvastatin (ATV), simvastatin (SIM) and pravastatin (PRA) in Mexican patients over 55 years old. METHODS: Efficacy data from STELLAR clinical trial (total cholesterol -TC-, LDL-C; HDL-C, triglycerides -TG-) was used as input to the model. Based on Framingham risk equations, 4 gender/risk Abstracts A195 cohorts were traced for 20 years (4-year Markov cycles) with 55-76 year old patients in order to predict primary and secondary CV events. Quarterly titration in year one was set up to a maximum dose of 20 mg RSV, 80 mg ATV, 80 mg SIM and 40 mg PRA based on TC target, whereas risk was calculated using average TC : HDL-C ratio of the 1000 simulated patients, with adjustment for Framingham's hypothesized over-prediction of Mexican risk. The economic analysis was done under private sector perspective with a 5% and 1.5% discount rate for costs and benefits, respectively. Unitary costs were obtained from NADRO (local wholesaler). Mexican Institute of Social Security costs and data from a Delphi Panel were used to estimate CV diseases' private costs. Disability-adjusted life years gained (DALYs) for each treatment regimen were estimated. Results are shown in natural units, while costs are expressed in US dollars. Sensitivity analysis included threshold, one-way scenarios and probabilistic analysis. RESULTS: RSV 10 mg for the 20-year horizon resulted in less primary and secondary events (197) and deaths (42), per 1000 patients, more DALYs (14.97) and lower per-patient treatment costs ($8134.57) than other statins on equivalent doses. Hence, RSV 10 mg is highly cost-effective with a cost per DALYs gained of $16,802.15 than comparators. Sensitivity analysis showed the robustness of results. CONCLU-SION: RSV is a cost-effective strategy: it yields fewer CV events, resulting in fewer deaths and significant economic saving for both patients and institutions. 5 Ghent University, Gent, Belgium OBJECTIVE: AVOID (Aliskiren in the Evaluation of Proteinuria in Diabetes) was a multicentre, randomised, double-blind, sixmonth study designed to assess the effect of adding aliskiren, an oral direct renin inhibitor, to losartan and optimal antihypertensive therapy (excluding ACE inhibitors), on the reduction in urinary albumin to creatinine ratio (UACR) in patients with hypertension, type 2 diabetes, and nephropathy. A costeffectiveness model was developed aiming to estimate the progression to end-stage renal disease (ESRD) and to project the associated costs and clinical outcomes of aliskiren in the UK setting. METHODS: A previously published Markov model of diabetic nephropathy and ESRD was adapted to incorporate treatment effects from AVOID, where aliskiren reduced mean UACR versus placebo by 20% (p = 0.0009). Transition probabilities from AVOID were used until patients reached UACR >1,900 mg/g, with probabilities from the Irbesartan in Diabetic Nephropathy Trial used thereafter. Direct medical costs were based on UK pharmacy costs and published sources. Annual discount rates of 3.5% were applied over the 20-year time horizon. RESULTS: Short-term therapy benefits associated with aliskiren were projected to increase life expectancy by 0.0983 years (7.9175 Ϯ 0.0434 versus 7.8192 Ϯ 0.0369 years), improve quality-adjusted life expectancy by 0.0878 quality-adjusted life years (QALYs) (5.3038 Ϯ 0.0444 versus 5.2160 Ϯ 0.0391 QALYs) and reduce the cumulative incidence of ESRD by 2.51 percent (19.52% versus 22.03%) compared to placebo. An incremental cost-effectiveness ratio of £12,073 per QALY gained was calculated for aliskiren, which is well below the willingness-topay threshold of the UK of £30,000 per QALY gained. Sensitivity analysis where the clinical benefit of aliskiren was extended beyond UACR >1900 mg/g, proved to be a cost saving strategy. CONCLUSION: Aliskiren would be considered cost-effective in the UK setting when added to losartan therapy due to the additional renal protection provided and a reduced incidence of ESRD. 
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RESULTS:
The model simulation predicts an equivalent utility score for all alternatives considered. From the payer perspective, the mean overall cost of the Gadofosveset-MRA strategy amount to $7814. In contrast, aggregated costs with either standard-MRA or -DSA reach $8637 and $9842, respectively. Thus, an imaging strategy with initial Gadofosveset-MRA is less costly than strategies initially using standard-MRA or -DSA. With regard to cost-effectiveness the additional costs per QALY gained by standard-MRA versus Gadofosveset-MRA amount to about $117,000 and about $178,000 for standard-DSA. The model was robust regarding probabilistic variations of all parameters. CONCLUSION: From the payer perspective in Canada, an imaging strategy starting with Gadofosveset-MRA represents a cost-effective option for the diagnostic work-up of severe PAOD (critical limb ischemia) compared to strategies with either standard-MRA or -DSA.
